Latest News

Yale Cancer Center researchers have made a significant advance in understanding the mechanisms of resistance to targeted therapies used in the treatment of lung adenocarcinoma driven by EGFR mutations.

David Rimm, MD, PhD, an Anthony N. Brady Professor of Pathology at Yale, discusses if pathologists are adequately quantifying the HER2 immunohistochemistry assay.

Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.

Each year, Connecticut Magazine recognizes some of the state’s best physicians, who provide exceptional care for patients, with its annual “Top Doctors” issue. This year’s list includes 82 physicians from Smilow Cancer Hospital and Yale Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state.

Recent studies from Marie Robert, MD, and David Rimm, MD, PhD, highlight the challenges pathologists face when interpreting PD-L1 expression using the combined positive score method of interpretation of immunohistochemistry results for patients with gastric/gastroesophageal junction/esophageal cancers.

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Presentation is about methods for assessment of multiple molecular variables on a single piece of tissue to better understand breast cancer (or really any cancer) with respect to progression or response or resistance to specific therapies.

The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.

An objective assessment of automated electronic tumor infiltrating lymphocytes percentage (eTILs%) scores is a strong prognostic marker in patients with early-stage melanoma. The study also identifies distinct TIL subpopulations that carry the prognostic values.